Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Zeprumetostat in R/R NK/T-Cell Lymphoma
NCT07502768Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zeprumetostat in Natural killer T-cell lymphoma (NKTL). Started Apr 2026; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT07502768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502768.